How much intravenous contrast is needed in FDG-PET/CT?
- 1 January 2005
- journal article
- review article
- Published by Georg Thieme Verlag KG in Nuklearmedizin-Nuclear Medicine
- Vol. 44 (S 01) , S32-S37
- https://doi.org/10.1055/s-0038-1625212
Abstract
Intravenous, iodinated contrast agents are used routinely for CT (ceCT) imaging but only applied reluctantly for FDGPET/ CT due to possible artefacts. Only for few oncological PET/CT indications, the role of IV contrast agent has been clarified. Essentially, if any knowledge regarding vascular structures or tumour invasion into adjacent structures are needed, a ceCT as part of the combined PET/CT exam should be implemented. However, for some indications like lymphoma, contrast seems not to be necessary. Therefore, imaging procedures for the use of IV contrast for PET/CT have to be adapted individually for each FDG-PET/CT indication to especially reduce unnecessary radiation burden to the patient. Die intravenöse Gabe von iodhaltigem Kontrastmittel (KM) erfolgt routinemäßig für die Computertomographie (KMCT). Wegen möglicher Bildartefakte wurde diese beim FDGPET/ CT zuerst nur vereinzelt verwendet. Zurzeit liegen nur begrenzte Ergebnisse bezüglich des Nutzens der KM beim FDG-PET/CT für onkologische Indikationen vor. Soll bei der FDG-PET/CT Untersuchung die Gefäßsituation oder eine Tumorinvasion in andere Strukturen beurteilt werden, so ist die Gabe von KM notwendig. Bei bestimmten Indikationen hingegen (z.B. Lymphom) scheint eine KM-Gabe nicht notwendig. Demzufolge muss die dezidierte Anwendung von KM für die jeweiligen FDG-PET/CT-Indikationen geklärt werden, um insbesondere unnötige Strahlenbelastung für den Patienten zu reduzieren.Keywords
This publication has 19 references indexed in Scilit:
- Non-Hodgkin Lymphoma and Hodgkin Disease: Coregistered FDG PET and CT at Staging and Restaging—Do We Need Contrast-enhanced CT?Radiology, 2004
- Staging of Non–Small-Cell Lung Cancer with Integrated Positron-Emission Tomography and Computed TomographyNew England Journal of Medicine, 2003
- Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scannerEuropean Radiology, 2003
- Respiration-induced Attenuation Artifact at PET/CT: Technical ConsiderationsRadiology, 2003
- The value of positron emission tomography (PET) imaging in disease staging and therapy assessmentAnnals of Oncology, 2002
- CT vs 68Ge attenuation correction in a combined PET/CT system: evaluation of the effect of lowering the CT tube currentEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s diseaseAnnals of Oncology, 1998
- Attenuation correction for a combined 3D PET/CT scannerMedical Physics, 1998
- Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomographyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.Radiology, 1997